• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Reviva Pharmaceuticals Holdings Inc.

    1/31/25 9:31:18 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RVPH alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 9)


    REVIVA PHARMACEUTICALS HOLDINGS, INC.

    (Name of Issuer)


    Common Stock, $0.001 par value

    (Title of Class of Securities)


    76152G100

    (CUSIP Number)


    Parag Saxena
    Vedanta Management, L.P., 250 West 55th Street, Ste 13D
    New York, NY, 10019
    212-710-5220

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    12/18/2024

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    76152G100


    1 Name of reporting person

    Vedanta Associates-R, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,967,768.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,967,768.00
    11Aggregate amount beneficially owned by each reporting person

    1,967,768.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.1 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    See Item 5 for additional information.


    SCHEDULE 13D

    CUSIP No.
    76152G100


    1 Name of reporting person

    Vedanta Associates, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF, WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,408,401.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,408,401.00
    11Aggregate amount beneficially owned by each reporting person

    3,408,401.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.9 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    See Item 5 for additional information.


    SCHEDULE 13D

    CUSIP No.
    76152G100


    1 Name of reporting person

    Beta Operators Fund, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,138,130.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,138,130.00
    11Aggregate amount beneficially owned by each reporting person

    2,138,130.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.4 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    See Item 5 for additional information.


    SCHEDULE 13D

    CUSIP No.
    76152G100


    1 Name of reporting person

    VEDANTA PARTNERS, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    5,376,169.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    5,376,169.00
    11Aggregate amount beneficially owned by each reporting person

    5,376,169.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    10.6 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    See Item 5 for additional information.


    SCHEDULE 13D

    CUSIP No.
    76152G100


    1 Name of reporting person

    Parag Saxena
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF, WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    INDIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    892,737.00
    8Shared Voting Power

    5,376,169.00
    9Sole Dispositive Power

    892,737.00
    10Shared Dispositive Power

    5,376,169.00
    11Aggregate amount beneficially owned by each reporting person

    6,268,906.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.4 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    See Item 5 for additional information.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.001 par value
    (b)Name of Issuer:

    REVIVA PHARMACEUTICALS HOLDINGS, INC.
    (c)Address of Issuer's Principal Executive Offices:

    Vedanta Management, L.P., 250 West 55th Street, Ste 13D, New York, NEW YORK , 10019.
    Item 1 Comment:
    This Amendment No. 9 to Schedule 13D (this "Amendment No. 9") filed on behalf of Parag Saxena, Vedanta Partners, LLC ("Vedanta Partners"), Beta Operators Fund, L.P. ("Beta Operators"), Vedanta Associates, L.P. ("Vedanta Associates"), and Vedanta Associates-R, L.P. ("Vedanta Associates-R" and collectively, the "Reporting Persons") amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on September 4, 2018, as amended and supplemented by Amendment No. 1, Amendment No. 2 and Amendment No. 3 on January 19, 2021, Amendment No. 4 on June 3, 2021, Amendment No. 5 on September 12, 2022, Amendment No. 6 on November 30, 2023, Amendment No. 7 on May 31, 2024 and Amendment No. 8 on August 23, 2024 (as amended, the "Schedule 13D"). Except as specifically provided herein, this Amendment No. 9 does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D.
    Item 5.Interest in Securities of the Issuer
    (a)
    The information set forth in rows 11 and 13 of the cover pages to this Amendment No. 9 are incorporated by reference into this Item 5. The percentages set forth in row 13 of each cover page are based on 46,602,699 outstanding shares of common stock, par value $0.0001 per share ("Common Stock"), of Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the "Issuer"), as of January 30, 2025, as reported directly by the Issuer to the Reporting Persons.
    (b)
    The information set forth in rows 7 through 10 of the cover pages to this Amendment No. 9 is incorporated by reference. The 1,966,768 shares of Common Stock reported as beneficially owned on this Amendment No. 9 by Vedanta Associates-R consist of the following: (i) 931,000 shares of Common Stock held directly, (ii) 521,934 shares of Common Stock underlying warrants, and (iii) 513,834 shares of Common Stock underlying pre-funded warrants. As a result, Vedanta Associates-R is deemed to beneficially own 4.1% of the outstanding shares of Common Stock of the Issuer as of December 20, 2024 (the "Filing Date"). The securities beneficially owned by Vedanta Associates-R excludes 689,150 shares of Common Stock issuable upon the exercise of 918,867 warrants held by Vedanta Associates-R, which contain an issuance limitation that prohibits the holder from exercising the warrants to the extent that after giving effect to such issuance after exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the other Reporting Persons) would beneficially own in excess of 4.99% of the shares of Common Stock outstanding immediately after giving effect to the issuance of the shares of Common Stock issuable upon exercise of the warrants (the "Blocker"). The 2,138,130 shares of Common Stock reported as beneficially owned on this Amendment No. 9 by Beta Operators consist of the following: (i) 399,000 shares of Common Stock held directly, (ii) 869,565 shares of Common Stock underlying warrants, and (iii) 869,565 shares of Common Stock underlying pre-funded warrants. As a result, Beta Operators is deemed to beneficially own 4.4% of the outstanding shares of Common Stock of the Issuer as of the Filing Date. The securities beneficially owned by Beta Operators excludes 299,250 shares of Common Stock issuable upon the exercise of 399,000 warrants held by Beta Operators, which are subject to the Blocker. The 3,408,401 shares of Common Stock reported as beneficially owned on this Amendment No. 9 by Vedanta Associates consist of the following: (i) 99,539 shares of Common Stock held directly, (ii) 399,000 shares of Common Stock held by Beta Operators, (iii) 869,565 shares of Common Stock underlying warrants held by Beta Operators, (iv) 585,366 shares of Common Stock underlying warrants held by Vedanta R2 Partners, LP ("Vedanta R2"), (v) 869,565 shares of Common Stock underlying pre-funded warrants held by Beta Operators, and (vi) 585,366 shares of Common Stock underlying pre-funded warrants held by Vedanta R2. As a result, Vedanta Associates is deemed to beneficially own 6.9% of the outstanding shares of Common Stock of the Issuer as of the Filing Date. The 5,375,169 shares of Common Stock reported as beneficially owned on this Amendment No. 9 by Vedanta Partners consist of the following: (i) 931,000 shares of Common Stock held by Vedanta Associates-R, (ii) 399,000 shares of Common Stock held by Beta Operators, (iii) 99,539 shares of Common Stock held by Vedanta Associates, (iv) 521,934 shares of Common Stock underlying warrants held by Vedanta Associates-R, (v) 869,565 shares of Common Stock underlying warrants held by Beta Operators, (vi) 585,366 shares of Common Stock underlying warrants held by Vedanta R2, (vii) 513,834 shares of Common Stock underlying pre-funded warrants held by Vedanta Associates-R, (vii) 869,565 shares of Common Stock underlying pre-funded warrants held by Beta Operators, and (viii) 585,366 shares of Common Stock underlying pre-funded warrants held by Vedanta R2. As a result, Vedanta Partners is deemed to beneficially own 10.6% of the outstanding shares of Common Stock of the Issuer as of the Filing Date. The 6,267,906 shares of Common Stock reported as beneficially owned on this Amendment No. 9 by Mr. Saxena consist of the following: (i) 871,337 shares of Common Stock held directly, (ii) 931,000 shares of Common Stock held by Vedanta Associates-R, (iii) 399,000 shares of Common Stock held by Beta Operators, (iv) 99,539 shares of Common Stock held by Vedanta Associates, (v) 521,934 shares of Common Stock underlying warrants held by Vedanta Associates-R, (vi) 869,565 shares of Common Stock underlying warrants held by Beta Operators, (vii) 585,366 shares of Common Stock underlying warrants held by Vedanta R2, (viii) 513,834 shares of Common Stock underlying pre-funded warrants held by Vedanta Associates-R, (vii) 869,565 shares of Common Stock underlying pre-funded warrants held by Beta Operators, (ix) 585,366 shares of Common Stock underlying pre-funded warrants held by Vedanta R2, and (x) 21,400 underlying options that are fully vested as of the Filing Date. As a result, Mr. Saxena is deemed to beneficially own 12.4% of the outstanding shares of Common Stock of the Issuer as of the Filing Date. The securities beneficially owned by Mr. Saxena exclude 8,200 shares underlying options that are unvested as of 60 days of the Filing Date. In accordance with Rule 13d-3, the beneficial ownership percentage for each Reporting Person assumes that the warrants and options that can be exercised within 60 days of the Filing Date, if any, held by such Reporting Person have been exercised, and that no other warrants or options have been exercised.
    (c)
    The Reporting Persons have not effected any transactions during the past sixty (60) days from the date of this filing in any securities of the Issuer, other than the options to purchase 8,200 shares of the Issuer's Common Stock that were granted to Mr. Saxena on December 10, 2024 in connection with his service as a director of the Issuer.
    (d)
    Except as otherwise reported herein, no person or entity other than the Reporting Persons have the right to receive, or the power to direct the receipt of dividends from, or the proceeds from the sale of the shares of the Common Stock reported on this Schedule 13D.
    (e)
    Each of Vedanta Associates-R and Beta Operators ceased to be a beneficial holder of more than five percent of the Issuer's Common Stock on December 18, 2024.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Vedanta Associates-R, LP
     
    Signature:By: Vedanta Partners, LLC, the general partner ("GP") of Vedanta Associates-R, L.P. /s/ Parag Saxena
    Name/Title:Parag Saxena/CEO of Vedanta Partners, LLC
    Date:01/31/2025
     
    Vedanta Associates, L.P.
     
    Signature:By: Vedanta Partners, LLC, the GP of Vedanta Associates, L.P. /s/ Parag Saxena
    Name/Title:Parag Saxena/CEO of Vedanta Partners, LLC
    Date:01/31/2025
     
    Beta Operators Fund, L.P.
     
    Signature:By: Vedanta Associates, L.P., the GP of Beta Operators Fund, L.P. By: Vedanta Partners, LLC, the GP of Vedanta Associates, L.P. /s/ Parag Saxena
    Name/Title:Parag Saxena/CEO of Vedanta Partners, LLC
    Date:01/31/2025
     
    VEDANTA PARTNERS, LLC
     
    Signature:/s/ Parag Saxena
    Name/Title:Parag Saxena/CEO
    Date:01/31/2025
     
    Parag Saxena
     
    Signature:/s/ Parag Saxena
    Name/Title:Parag Saxena/Individual
    Date:01/31/2025
    Get the next $RVPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RVPH

    DatePrice TargetRatingAnalyst
    9/20/2023$12.00Buy
    ROTH MKM
    6/8/2023$17.00Speculative Buy
    The Benchmark Company
    1/24/2022$10.00Buy
    HC Wainwright & Co.
    7/26/2021$10.00Buy
    Maxim Group
    More analyst ratings

    $RVPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Reviva Pharmaceuticals Holdings Inc.

      SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

      11/14/24 5:16:56 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Reviva Pharmaceuticals Holdings Inc.

      SC 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

      11/14/24 4:15:57 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Reviva Pharmaceuticals Holdings Inc.

      SC 13D/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

      8/23/24 4:07:26 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Narayan Prabhu

      4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

      2/18/25 4:30:51 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Bhat Laxminarayan

      4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

      2/18/25 4:30:30 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Patel Purav

      4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

      12/12/24 4:35:57 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $RVPH
    Financials

    Live finance-specific insights

    See more

    $RVPH
    Leadership Updates

    Live Leadership Updates

    See more

    $RVPH
    SEC Filings

    See more

    $RVPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Reviva to Participate in the Citizens Life Sciences Conference

      CUPERTINO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Citizens Life Sciences Conference, taking place May 7-8, 2025, in New York, NY. Citizens Life Sciences Conference Format: Corporate Update / Fireside ChatDate: Thursday, May 8, 2025Time: 10:30 a.m. ETLocation: New York, NYWebcast Link: Click Here About Reviva Reviva is

      4/29/25 8:00:00 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

      CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present a late-breaking poster presentation on the RECOVER 12-month open label extension trial for brilaroxazine in schizophrenia at the 2025 American Society of Clinical Psychopharmacology (ASCP) annual meeting, taking place May 27-30, 2025, in Scottsdale, AZ. Details for the poster

      4/24/25 8:00:00 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

      – Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial – – Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 – – Full data set from RECOVER OLE expected in Q2 2025 – CUPERTINO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the full year ended December 31, 2024

      3/31/25 4:05:15 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

      - Successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in Positive and Negative Syndrome Scale (PANSS) total score vs. placebo at week 4, p<0.001 - - Statistically significant and clinically meaningful reductions in all major symptom domains and secondary endpoints at week 4 with 50 mg of brilaroxazine vs. placebo - - Generally well-tolerated with a side effect profile comparable to placebo for the 15 and 50 mg doses of brilaroxazine; discontinuation rates for brilaroxazine lower than placebo - - Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 - - Conference call and webcast

      10/30/23 7:30:00 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology: https://www.redchip.com/assets/access/stss_accessReviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAmerican Resources Corp: https://www.redchip.com/assets/access/arec_accessAbout The RedChip

      9/29/23 9:00:00 AM ET
      $AREC
      $RVPH
      $STSS
      Coal Mining
      Energy
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Reviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Rel

      9/22/23 1:30:00 PM ET
      $ARDS
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Appoints John H. Johnson as Executive Chairman

      Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John

      12/20/24 7:00:00 AM ET
      $APLT
      $RVPH
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Reviva Pharmaceuticals Holdings Inc.

      S-8 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

      4/3/25 7:55:15 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-K filed by Reviva Pharmaceuticals Holdings Inc.

      NT 10-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

      3/31/25 5:16:54 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

      3/31/25 4:12:22 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM initiated coverage on Reviva Pharmaceuticals with a new price target

      ROTH MKM initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      9/20/23 7:22:47 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The Benchmark Company initiated coverage on Reviva Pharmaceuticals with a new price target

      The Benchmark Company initiated coverage of Reviva Pharmaceuticals with a rating of Speculative Buy and set a new price target of $17.00

      6/8/23 7:41:12 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Reviva Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $10.00

      1/24/22 6:07:15 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care